SweetValueLab
Write for us

Stryker Corporation — Intrinsic Value & Fair Price

SYK
NYSEHealthcareMedical - DevicesCIK 0000310764stryker.comAbout SYK
Last close · Oct 16, 2026294.66+1.43 (+0.49%)
Market cap$113.0B
Model value · DCF · Perpetuity growth · 5y
261.75
Stryker closed at $294.66 — overvalued by 13% vs model.
157.06the model's range677.77

DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.

Other models
76.85 – 520.94
Wall St. target
370.00 20% below
Above model, 1y
21 of 21 days

Price and model value

Embed this card

SYK's close against its model value, as a 420×168 card for your own page. It updates nightly with this site and links back here.

Free to embed; keep the attribution link.
Loading chart…
What the marks mean
Daily close

Dividends

Quarterly · as of Oct 16, 2026
Yield, trailing 12 months
1.19%
Past 2 years
low 0.81%high 1.29%
Dividends per share, a year at a time
$2.52Sep ’21$2.78Sep ’22$3.00Sep ’23$3.20Sep ’24$3.36Sep ’25$3.52TTM
Dividends / free cash flow, FY2025
30.0%
Raised
16 years in a row
Growth, 5 yrs
6.9% a year
Last change
+4.8% · Dec 2025
Every payment, with ex-dates · latest $0.88, paid Oct 30, 2026

Research on SYK

No posts on SYK yet.
Studied SYK from its filings? Guest posts are reviewed before they go live.Write about SYK →

How it is valued

Valued asMature & Stable
Moderate growth (~11% recent)Moderate margins (13% net margin)Pays dividendsHighly cyclical earnings
What growth the price implies: the reverse DCF

Key figures

FY2025
P/E
35.1×
EV / EBITDA
19.8×
FCF yield
3.8%
Dividend yield, TTM
1.19%
Beta
0.78
Cost of capital (WACC)
8.01%
Full financials

Analyst actions

third-party, quoted
10-12BTIG · target316.00
10-06Truist Financial · target310.00
10-06Barclays · target375.00
08-13Wolfe Research · “Peer Perform” from “Outperform”downgrade
Ratings, targets and estimates

The weekly

One email a week across every stock we cover: 13F filings, insider trades, earnings and new research. It covers the whole market, not just SYK. No account.

About Stryker

Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.

CEO
Kevin A. Lobo
Headquarters
Portage, MI
Employees
56,000
IPO
1980-03-17
Full company profile

Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; the formulas are in how we value a stock.